All In MedTech

FDA Clearance Tracker · P230001

ColoSense®

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: May 3, 2024 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product codeBreakthrough

Decided

May 3, 2024

Approved

Time to decision

469 days

Received Jan 20, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P230001
Device name
ColoSense®
Applicant location
St. Louis, MO
Received
Jan 20, 2023
Decided
May 3, 2024
Decision
Approved
Supplements
12 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code SBB

FDA's approval statement

As written in FDA's record.

ColoSense is a qualitative in vitro diagnostic test intended for the detection of colorectal neoplasia associated RNA markers and for the presence of occult hemoglobin in human stool. A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA) or serrated precancerous lesions (SPL) and should be followed by a colonoscopy. ColoSense is indicated as a screening test for adults, 45 years of age or older, who are at average-risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code SBB (System, Colorectal Neoplasia, RNA Markers and Hemoglobin detection).
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

Other decisions for Geneoscopy, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.